Journal of AdvancedMedical and Dental Sciences Research

Background:It has become increasingly recognized that chronic obstructive pulmonary disease (COPD) is a systemic disorder characterized not only by pulmonary but also by systemic inflammation.Statins, also known as 3-Hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors, are the most common medications used to treat hyperlipidaemia. Hence; we conducted the present investigation to assess the effect of rosuvastatin in patients with chronic obstructive pulmonary disease (COPD). Materials & methods: The present investigation included evaluation of effect of rosuvastatin in patients with chronic obstructive pulmonary disease (COPD). A total of 30 patients were included in the present study. Random distribution of all the patients was done into two study groups, with 15 patients in each group. The first group received rosuvastatin 10 mg orally once daily and the second group received placebo matching the active drug. Evaluation of the patients was done after 90 days for assessing the outcome. Following Pulmonary function indices were assessed for assessing the outcome:Forced vital capacity (FVC),Forced expiratory volume at 1 s (FEV1), and FEV1/FVC.Comparison of the results was done by SPSS software. Results: A total of 30 patients with COPD were included in the present study. Mean age of the patients of the placebo group and the Rosuvastatin group was found to be 60.5 years and 62.1 years respectively. We observed a significant alteration in the mean pulmonary functional indices while comparing the values in the placebo group and Rosuvastatin group (P-value < 0.05). Conclusion: A significant decrease in the COPD exacerbation was observed in patients on Rosuvastatin therapy. Key words: Chronic obstructive pulmonary disease, Rosuvastatin.